Shanghai Henlius Biotech (SEHK: 2696) has started an international phase 1 trial for its nivolumab biosimilar HLX18 targeting multiple solid tumors. Despite this progress, the company’s share price has faced a decline of 5.79% over the past month and 28.49% over the last three months. Currently, its price-to-earnings (P/E) ratio stands at 33.7x—above industry averages, suggesting it may be overvalued, while analysts predict higher intrinsic values. Opinions diverge, as a discounted cash flow model indicates the stock is undervalued at HK$59.35 compared to an estimated future cash flow value of HK$192.31. Investors are encouraged to weigh the potential risks and rewards before making decisions.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-advances-pipeline-as-fair
